AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab, a selective pathogenic T cell depleter in Phase 2b trials for moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist in Phase 1b trials for celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2 modulator in Phase 1a trials. AnaptysBio also manages financial collaborations for out-licensed therapeutic antibodies, including a PD-1 antagonist (Jemperli) partnered with GSK and an IL-36R antagonist (imsidolimab) partnered with Vanda Pharmaceuticals. The company generates revenue from milestones, royalties, and license fees under these agreements. In September 2025, the board approved plans to separate the business into two independent public companies: one to manage the financial collaborations and another to continue the clinical-stage development of its autoimmune pipeline. The separation is expected to be completed in the second quarter of 2026.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage anaptysbio.com
Sector Healthcare IR page ir.anaptysbio.com
Tags
immunology, autoimmune diseases, inflammatory diseases, rheumatoid arthritis, celiac disease, eosinophilic esophagitis, antibody therapeutics, t cell depletion, cd122 antagonist, bdca2 modulator, royalty management, rosnilimab, ANB033, ANB101, Jemperli, dostarlimab-gxly, imsidolimab, GSK, Vanda Pharmaceuticals
Press page —

Metrics

Valuation  
Market cap $ 1.393B
Market cap (USD) $ 1.393B
P/E -101.18
PEG —
P/BV 66.93
P/S 5.94
P/OCF 70.75
P/FCF 71.06
Dividend yield —
Turnover / mcap —
Returns  
ROE -24.5%
ROI —
ROIC —
Profit margin -5.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score -20.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 234.603M 91.28M 17.157M 10.287M 63.175M 75M 8M 5M 10M 16.684M
Net profit -13.232M -145.231M -163.619M -128.724M -57.796M -19.931M -97.336M -61.656M -30.07M -4.259M
Free cash flow 19.61M -135.695M -121.607M -73.951M -47.286M -14.726M -70.322M -49.569M -19.728M -9.08M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 48.48 13.24 21.42 30.99 34.75 21.5 16.25 63.79 100.72 —
Price performance 12m 2.66 -0.38 -0.31 -0.11 0.62 0.32 -0.75 -0.37 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.23M 0.00 0.00 0.00 0.00 876,000 1.42M 6.85M 40.8M 33.9M
↳ YoY growth -0.1% -100.0% +62.0% +382.8% +495.0% -17.0%
↳ 5y CAGR -6.5%
Lease liabilities (USD) — — 2.3M 1.53M 342,000 21M 19.5M 17.8M 16M 14.1M
Cash and deposits (USD) 51.2M 81.2M 114M 171M 250M 496M 71.3M 36M 123M 238M
Right-of-use assets (USD) — — 2.1M 1.4M 344,000 19.6M 17.9M 16.2M 14.4M 12.5M
Cash flow detail
Operating cash flow (USD) -9.03M -19.4M -48.5M -69.5M -14.2M -45.9M -73.6M -121M -135M 19.7M
Purchases of property, plant and equipment (USD) 50,000 -290,000 -1.06M -805,000 -569,000 -1.37M -358,000 -807,000 -358,000 -87,000
Change in payables (cash effect) (USD) 1.25M 2.22M 7.08M 14.5M -8.88M -4.74M 9.7M 10.9M -33.8M -87.3M
Share buybacks (cash effect) (USD) 1,000 0.00 0.00 — — 0.00 0.00 -50M -456,000 -68.6M
Interest paid (cash effect) (USD) -354,000 -1.09M -1.04M -424,000 -4,000 0.00 0.00 0.00 -42.1M -80M
Share-based compensation (USD) 1.16M 4.38M — — — 15.3M 27.4M 33.2M 34M 36.1M
Free cash flow (OCF - PPE - intangibles) (USD) -9.08M -19.7M -49.6M -70.3M -14.7M -47.3M -74M -122M -136M 19.6M
Income detail
Research and development expense (USD) 15.4M 29.4M 56.2M 99.3M 80M 98.5M 88.8M 132M 164M 136M
↳ 5y CAGR +63.1% +35.8% +44.9% +24.7% +18.7% +10.5% +11.2%
Total comprehensive income (USD) -4.26M -30.5M -61.5M -96.8M -20.3M -58.2M -134M -159M -144M -13.6M
Comprehensive income to owners (USD) -4.26M -30.5M -61.5M -96.8M -20.3M -58.2M -134M -159M -144M -13.6M
Reported Mar 5, 2018 Mar 5, 2018 Feb 25, 2021 May 6, 2020 May 4, 2021 Mar 11, 2024 Mar 11, 2024 Feb 27, 2025 Feb 27, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth

•Jemperli approved in the U.S. as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer

•Litigation with GSK and Tesaro: post-trial hearing held on October 20, 2026, with a judgment anticipated in calendar Q4 2026 or Q1 2027

SAN DIEGO, November 12, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update.

“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications,” said Daniel Faga, president and chief executive officer.

October 19, 2026

PDF Version

  • Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment

  • No disease recurrences reported among responders after median follow up of more than 2 years

  • Jemperli monotherapy could help eligible patients avoid chemotherapy, radiation and surgery

  • GSK to present full data from the AZUR-1 interim analysis as a late-breaking abstract at ESMO Congress 2026 in Madrid, Spain on October 25, 2026

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer.

Jemperli received FDA Fast Track and Breakthrough Therapy designations for this indication. The application was also granted Priority Review and received the National Priority Voucher, resulting in an accelerated approval ahead of the February 2027 PDUFA date.

This approval is supported by data from the AZUR-1 trial. The study met its primary objective, demonstrating a significant proportion of participants achieved sustained clinical complete responses at 12 months (cCR12), with data continuing to mature.

Investigator-assessed data, a clinically relevant endpoint, showed 68% of evaluable patients (98/144; 95% CI: 60%, 76%) achieved cCR12. In an exploratory analysis, 76% (110/144; 95% CI: 69%, 83%) of evaluable patients had no evidence of cancer one year or more after treatment. This includes 68% (98/144) (95% CI: 60%, 76%) of patients who reached cCR12 without surgery, plus other participants (n=12) who had their complete response confirmed through tissue analysis after surgery (pathological complete response, or pCR). No disease recurrences have been reported among responders to date, after a median follow up of more than two years.

Data on the primary objective, cCR12 assessed by independent central review, continue to mature. 47% (54/116) (95% CI: 37%, 56%) of evaluable patients have achieved cCR12. An additional 38 participants who are still progressing through to 12 month follow up have already achieved a clinical complete response.

The safety profile of Jemperli was generally consistent with its established profile across solid tumors. Serious adverse reactions occurred in 20% of patients receiving Jemperli, and the most common adverse reactions were fatigue (32%), rash (22%), diarrhea (18%) and pruritus (17%). Jemperli was permanently discontinued due to adverse reactions in 3% of patients.

GSK plans to present full data from the AZUR-1 interim analysis as a late-breaking abstract at ESMO Congress 2026 in Madrid, Spain on October 25, 2026.

Current standard of treatment for locally advanced rectal cancer includes chemotherapy, radiation and surgery1, but these can have lasting consequences, including bowel, urinary and sexual dysfunction, secondary cancers and infertility.2,3 For patients with MSI-H/dMMR tumors, a biomarker found in around 5-10% of rectal cancers, Jemperli monotherapy could help avoid these interventions.4

The AZUR-1 sBLA is being reviewed under Project Orbis, an FDA Oncology Center of Excellence initiative that enables concurrent review by international health authorities. Regulatory reviews are ongoing in participating countries.

AboutJemperli(dostarlimab)

Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. In the United States, Jemperli is currently approved for endometrial cancer, rectal cancer and dMMR solid tumors, and is currently being studied as monotherapy in colon cancer and head and neck squamous cell carcinoma.

Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a Collaboration and Exclusive License Agreement signed in March 2014. Under this agreement, GSK is conducting ongoing research, development, commercialization, and manufacturing of Jemperli.

More information about the product and its currently approved indications is available at U.S. product information and EU product information.

About Anaptys

Anaptys manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to future commercial and regulatory developments for Jemperli and Quimilza; and future royalty amounts. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to commercial success of the Company’s licensed products, the company’s ability to protect its financial collaborations and return value to its shareholders, the company’s ability to operate efficiently with a limited staff, and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

September 21, 2026

PDF Version

  • Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth

  • Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision

  • Litigation with GSK and Tesaro: trial held in July; post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.

“Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro,” said Daniel Faga, president and chief executive officer. “In addition to Jemperli, we anticipate FDA approval of Quimilza in GPP in December 2026.”

GSKJemperliFinancial Collaboration

  • GSK announced strong commercial performance for Jemperli

  • $331 million (£248 million) in global net sales for the three months ended June 30, 2026, representing 26% year-over-year growth1

  • $644 million (£480 million) in global net sales for the six months ended June 30, 2026, representing 34% year-over-year growth1

  • Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK’s peak monotherapy sales guidance of > $2.7 billion2

  • Anaptys estimates Sagard will have accrued ~$301 million in royalties and sales milestones through Q2 2026 and anticipates paydown of the remaining ~$299 million non-recourse debt monetization in the second half of 2027

  • Jemperli development and regulatory updates include:

  • AZUR-1 – pivotal Phase 2 – dostarlimab monotherapy in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer

  • In July 2026, GSK announced positive interim results from the trial, which met its primary objective by demonstrating a meaningful and sustained clinical complete response rate for 12 months (cCR12) with no detectable signs of cancer for at least one year

  • The FDA has assigned a PDUFA action date of February 2027

  • Received an FDA Commissioner’s National Priority Voucher (CNPV) in Nov. 2025; eligible for an expedited review which could result in an earlier FDA decision

  • GSK to present first results from the AZUR-1 trial as a late-breaking abstract at ESMO Congress 2026 in Madrid, Spain on Oct. 25, 2026

  • AZUR-2 – pivotal Phase 3 – dostarlimab versus standard of care in untreated TN40 or stage III dMMR/ MSI-H resectable colon cancer

  • Data expected in 2028

  • AZUR-4 – Phase 2 – dostarlimab plus chemotherapy versus standard of care (chemotherapy) in untreated stage III MMRp/MSS resectable colon cancer

  • Primary completion date in Q4 2026

  • JADE – pivotal Phase 3 – dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 CPS≥1) post chemoradiation

  • Data expected in 2028

VandaQuimilza(imsidolimab) Financial Collaboration

  • FDA target action date (PDUFA) of Dec. 12, 2026, for Quimilza in generalized pustular psoriasis (GPP)

  • In August 2026, Vanda announced it received Orphan Designation from the European Commission for imsidolimab for the treatment of GPP

GSK and Tesaro Litigation Update

  • The trial was held before the Delaware Chancery Court from July 14-17, 2026

  • The Court has requested the parties submit post-trial briefs in advance of a post-trial hearing, which has been scheduled for October 20, 2026

  • Anaptys filed its opening post-trial brief on August 21, 2026, GSK and Tesaro will file their answering post-trial brief on or before September 25, 2026, and Anaptys will file its reply post-trial brief on or before October 9, 2026

  • Anaptys is seeking reversion of Jemperli rights as a remedy; the Company anticipates a judgement in Q4 2026 or Q1 2027

Second Quarter Financial Results

  • The separation of AnaptysBio and First Tracks Biotherapeutics was completed on April 20, 2026. Beginning in the second quarter of 2026, AnaptysBio reclassified historical First Tracks Biotherapeutics, Inc. related assets, liabilities and expenses as discontinued operations.

  • On May 18, 2026, Anaptys changed its fiscal year-end from December 31 to June 30. The Company will begin to file quarterly reports based on the new fiscal year beginning with the quarter ending September 30, 2026.

  • As of June 30, 2026, Anaptys has not repurchased any shares under its $100 million Stock Repurchase Plan, which will expire on December 31, 2026, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.

  • Cash, cash equivalents and investments totaled $164.1 million as of June 30, 2026, compared to $211.6 million as of December 31, 2025, for a decrease of $47.5 million due primarily to $72.9 million for operating activities offset by $25.4 million received from stock option exercises.

  • Collaboration revenue was $27.5 million and $53.0 million for the three and six months ended June 30, 2026, compared to $22.3 million and $50.0 million for the three and six months ended June 30, 2025. The increase is primarily due to Jemperli royalties increasing 25% and 34% for the three and six months ended June 30, 2026, offset by $9.7 million in revenue recognized for the Vanda license agreement for the three month and six months ended June 30, 2025.

  • General and administrative expenses were $16.0 million and $23.4 million for the three and six months ended June 30, 2026, compared to $4.0 million and $8.3 million for the three and six months ended June 30, 2025. The increase was due primarily to legal costs for the separation of the company and the GSK and Tesaro lawsuit and non-cash stock compensation.

  • Research and development expenses from continuing operations were a negative $2.7 million for the six months ended June 30, 2026, compared to a negative $1.7 million six months ended June 30, 2025. The negative balance for the six months ended June 30, 2026, was primarily due adjustments related to the closeout of clinical contracts reducing expenses incurred prior to the separation.

  • Benefit for income taxes for continuing operations was $181.5 million for the six months ended June 30, 2026. The benefit recognized was primarily due to the release of the valuation allowance on deferred tax assets due to the anticipated usage of deferred tax assets in the future due to the separation from First Tracks Biotherapeutics.

  • Net income from continuing operations was $177.3 million and $176.4 million for the three and six months ended June 30, 2026, or a basic net income per share of $6.06 and $6.09, compared to a net income from continuing operations of $5.7 million and $16.6 million for the three and six months ended June 30, 2025, or a basic net income per share of $0.20 and $0.56.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to future commercial and regulatory developments for Jemperli and Quimilza, future royalty amounts, the Company’s expected paydown of its obligations to Sagard, and the outcome of the Company’s ongoing litigation with GSK. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to commercial success of the Company’s licensed products, the company’s ability to protect its financial collaborations and return value to its shareholders, the company’s ability to operate efficiently with a limited staff, and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

About Anaptys

Anaptys manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Prompts

AnaptysBio, Inc. (ticker ANAB), listed in United States.

ETFs Holding AnaptysBio, Inc.

ETF Weight in ETF Shares Market value As of
HELX 1.04% 4,290 $ 289.575K Jun 30, 2026
FSML 0.99% 18,344 $ 1.238M Jun 30, 2026
CANC 0.88% 32,744 $ 1.867M Aug 31, 2026
LITL 0.51% 639 $ 29.145K Nov 17, 2026
AFSM 0.33% 10,496 $ 479.982K Nov 16, 2026
FSCC 0.24% 15,112 $ 861.837K Aug 31, 2026
ESSC 0.21% 1,384 $ 73.85K Jul 31, 2026
VFMO 0.15% 50,176 $ 2.862M Aug 31, 2026
FSEG 0.11% 96 $ 6,480.00 Jun 30, 2026
RESM 0.06% 32 $ 2,160.00 Jun 30, 2026
DFAS 0.02% 141,664 $ 6.767M Nov 12, 2026
FESM 0.01% 9,970 $ 672.975K Jun 30, 2026
MSSM 0.01% 1,293 $ 73.74K Aug 31, 2026
DFUS 0.00% 6,052 $ 289.104K Nov 12, 2026
EBI 0.00% 18 $ 1,026.54 Aug 31, 2026